Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma Journal Article
| Authors: | Mayerhoefer, M. E.; Riedl, C. C.; Kumar, A.; Gibbs, P.; Weber, M.; Tal, I.; Schilksy, J.; Schöder, H. |
| Article Title: | Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma |
| Abstract: | Purpose: To determine whether [18F]FDG PET/CT-derived radiomic features alone or in combination with clinical, laboratory and biological parameters are predictive of 2-year progression-free survival (PFS) in patients with mantle cell lymphoma (MCL), and whether they enable outcome prognostication. Methods: Included in this retrospective study were 107 treatment-naive MCL patients scheduled to receive CD20 antibody-based immuno(chemo)therapy. Standardized uptake values (SUV), total lesion glycolysis, and 16 co-occurrence matrix radiomic features were extracted from metabolic tumour volumes on pretherapy [18F]FDG PET/CT scans. A multilayer perceptron neural network in combination with logistic regression analyses for feature selection was used for prediction of 2-year PFS. International prognostic indices for MCL (MIPI and MIPI-b) were calculated and combined with the radiomic data. Kaplan–Meier estimates with log-rank tests were used for PFS prognostication. Results: SUVmean (OR 1.272, P = 0.013) and Entropy (heterogeneity of glucose metabolism; OR 1.131, P = 0.027) were significantly predictive of 2-year PFS: median areas under the curve were 0.72 based on the two radiomic features alone, and 0.82 with the addition of clinical/laboratory/biological data. Higher SUVmean in combination with higher Entropy (SUVmean >3.55 and entropy >3.5), reflecting high “metabolic risk”, was associated with a poorer prognosis (median PFS 20.3 vs. 39.4 months, HR 2.285, P = 0.005). The best PFS prognostication was achieved using the MIPI-bm (MIPI-b and metabolic risk combined): median PFS 43.2, 38.2 and 20.3 months in the low-risk, intermediate-risk and high-risk groups respectively (P = 0.005). Conclusion: In MCL, the [18F]FDG PET/CT-derived radiomic features SUVmean and Entropy may improve prediction of 2-year PFS and PFS prognostication. The best results may be achieved using a combination of metabolic, clinical, laboratory and biological parameters. © 2019, The Author(s). |
| Keywords: | adult; cancer survival; middle aged; major clinical study; cancer combination chemotherapy; cytarabine; ibritumomab tiuxetan; rituximab; drug megadose; follow up; progression free survival; mantle cell lymphoma; bendamustine; autologous stem cell transplantation; retrospective study; prediction; lymphoma; fluorodeoxyglucose f 18; radioimmunotherapy; glycolysis; fdg; pet/ct; standardized uptake value; glucose metabolism; ofatumumab; metabolic tumor volume; maximum standardized uptake value; entropy; cancer prognosis; prognosis; human; male; female; article; feature selection; positron emission tomography-computed tomography; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; mean standardized uptake value; multilayer perceptron; peak standardized uptake value |
| Journal Title: | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume: | 46 |
| Issue: | 13 |
| ISSN: | 1619-7070 |
| Publisher: | Springer |
| Date Published: | 2019-12-01 |
| Start Page: | 2760 |
| End Page: | 2769 |
| Language: | English |
| DOI: | 10.1007/s00259-019-04420-6 |
| PUBMED: | 31286200 |
| PROVIDER: | scopus |
| PMCID: | PMC6879438 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work